HC Wainwright reaffirmed their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.
InflaRx Price Performance
InflaRx stock opened at $1.57 on Wednesday. The stock’s 50-day moving average is $1.49 and its 200-day moving average is $1.50. The company has a market cap of $92.45 million, a price-to-earnings ratio of -2.01 and a beta of 1.57. InflaRx has a 12 month low of $1.14 and a 12 month high of $3.08.
InflaRx (NASDAQ:IFRX – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.04 million. InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. Research analysts anticipate that InflaRx will post -0.98 EPS for the current year.
Institutional Investors Weigh In On InflaRx
About InflaRx
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Featured Articles
- Five stocks we like better than InflaRx
- Consumer Staples Stocks, Explained
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- 3 Healthcare Dividend Stocks to Buy
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- How to Calculate Inflation Rate
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.